BCL2 and diffuse large B-cell lymphoma: More precisely, combinations of RiBi inhibitors with drugs stabilizing p53 in a RiBi-independent manner, such as MDM2i and etoposide, restored efficient stabilization of p53 in BCL-2 overexpressing DLBCL cells.